231 related articles for article (PubMed ID: 28235630)
21. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Mithraprabhu S; Kalff A; Chow A; Khong T; Spencer A
Epigenetics; 2014 Nov; 9(11):1511-20. PubMed ID: 25482492
[TBL] [Abstract][Full Text] [Related]
22. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
23. Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.
Wang H; Kohashi K; Yoshizumi T; Okumura Y; Tanaka Y; Shimokawa M; Iwasaki T; Aishima S; Maehara Y; Oda Y
Hum Pathol; 2017 Jun; 64():69-75. PubMed ID: 28411180
[TBL] [Abstract][Full Text] [Related]
24. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
Tracht J; Zhang K; Peker D
J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
[TBL] [Abstract][Full Text] [Related]
25. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior.
Díaz Del Arco C; Esteban López-Jamar JM; Ortega Medina L; Díaz Pérez JÁ; Fernández Aceñero MJ
Diagn Cytopathol; 2017 Jan; 45(1):29-35. PubMed ID: 27863178
[TBL] [Abstract][Full Text] [Related]
26. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
27. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma.
Huang R; Zhang X; Sophia S; Min Z; Liu X
Anticancer Drugs; 2018 Apr; 29(4):364-370. PubMed ID: 29481474
[TBL] [Abstract][Full Text] [Related]
29. Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Jin Z; Jiang W; Jiao F; Guo Z; Hu H; Wang L; Wang L
Int J Clin Exp Pathol; 2014; 7(9):5872-9. PubMed ID: 25337229
[TBL] [Abstract][Full Text] [Related]
30. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
[TBL] [Abstract][Full Text] [Related]
31. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
Weichert W; Röske A; Gekeler V; Beckers T; Ebert MP; Pross M; Dietel M; Denkert C; Röcken C
Lancet Oncol; 2008 Feb; 9(2):139-48. PubMed ID: 18207460
[TBL] [Abstract][Full Text] [Related]
32. The expression of histone deacetylase 1, but not other class I histone deacetylases, is significantly increased in endometriosis.
Samartzis EP; Noske A; Samartzis N; Fink D; Imesch P
Reprod Sci; 2013 Dec; 20(12):1416-22. PubMed ID: 23690335
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
34. Elevated immunoreactivity against class I histone deacetylases in adenomyosis.
Liu X; Nie J; Guo SW
Gynecol Obstet Invest; 2012; 74(1):50-5. PubMed ID: 22539030
[TBL] [Abstract][Full Text] [Related]
35. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
[TBL] [Abstract][Full Text] [Related]
37. Heme oxygenase-1 promoter polymorphism is a predictor of disease relapse in pancreatic neuroendocrine tumors.
Vashist YK; Uzunoglu G; Deutsch L; Kalinin V; Zehler O; Alzadjali A; Kutup A; Izbicki JR; Yekebas EF
J Surg Res; 2011 Apr; 166(2):e121-7. PubMed ID: 21236443
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
[TBL] [Abstract][Full Text] [Related]
39. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors.
Fujimori N; Osoegawa T; Lee L; Tachibana Y; Aso A; Kubo H; Kawabe K; Igarashi H; Nakamura K; Oda Y; Ito T
Scand J Gastroenterol; 2016; 51(2):245-52. PubMed ID: 26513346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
